Market Overview
Global Drug-eluting Coronary Stents market size was valued at USD 1.75 billion in 2024. The market is projected to grow from USD 1.82 billion in 2025 to USD 2.37 billion by 2031, exhibiting a CAGR of 4.5% during the forecast period.
Drug-eluting coronary stents are medical devices coated with medication designed to reduce the risk of artery re-blockage following implantation. These stents are essential in treating coronary artery disease by keeping arteries open and releasing drugs gradually to prevent restenosis, a common complication after angioplasty. They represent a significant advancement over bare-metal stents, offering improved long-term outcomes for patients with cardiovascular conditions.
USD 1.75 billion in 2024
2032 USD 2.37 billion by 2031
of 4.5%
However, challenges like stringent regulatory approvals and high development costs persist.
The market is segmented based on type into:
Stent Diameter ≤4mm
Subtypes: Cobalt-chromium based and others
Stent Diameter >4mm
By Application
Manufacturers are focusing on recent developments like bioresorbable coatings and personalized stent designs to address these challenges. The market is segmented based on application into:
ASCs (Ambulatory Surgical Centers) Hospitals Cardiology Centers
Others
Portable Neuromonitoring Device Market
The competitive environment features major players such as Medtronic, Boston Scientific, Biosensors, Terumo, MicroPort, Lepu Medical, B. Braun, Atrium Medical, SINOMED, LBC, and Essen Technology, who collectively drive innovation through mergers, acquisitions, and R&D investments to capture market share in this evolving industry.
Our Key Players
Medtronic (Ireland)
Boston Scientific (U.S.)
Biosensors (Singapore)
Terumo (Japan)
MicroPort Scientific Corporation (China)
Lepu Medical Technology (Beijing) Co., Ltd. (China)
https://www.24lifesciences.com/dow
https://www.24lifesciences.com
